Citigroup’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.1M Buy
66,639
+45,045
+209% +$10.6M 0.01% 1145
2026
Q1
$4.31M Buy
21,594
+3,302
+18% +$653K ﹤0.01% 2081
2025
Q4
$3.46M Sell
18,292
-3,095
-14% -$595K ﹤0.01% 2283
2025
Q3
$3.79M Sell
21,387
-8,287
-28% -$1.23M ﹤0.01% 2182
2025
Q2
$3.37M Sell
29,674
-16
-0.1% -$1.71K ﹤0.01% 2229
2025
Q1
$3.12M Buy
29,690
+1,702
+6% +$192K ﹤0.01% 2324
2024
Q4
$3M Buy
27,988
+2,408
+9% +$272K ﹤0.01% 2457
2024
Q3
$2.56M Buy
25,580
+11,107
+77% +$1.12M ﹤0.01% 2448
2024
Q2
$1.22M Buy
14,473
+1,211
+9% +$96.4K ﹤0.01% 2761
2024
Q1
$969K Buy
13,262
+816
+7% +$60.2K ﹤0.01% 3049
2023
Q4
$889K Buy
12,446
+3,669
+42% +$217K ﹤0.01% 2925
2023
Q3
$526K Sell
8,777
-7,295
-45% -$480K ﹤0.01% 3018
2023
Q2
$1.16M Buy
16,072
+3,676
+30% +$276K ﹤0.01% 2722
2023
Q1
$912K Sell
12,396
-572
-4% -$40.7K ﹤0.01% 2633
2022
Q4
$866K Sell
12,968
-54,938
-81% -$3.57M ﹤0.01% 2746
2022
Q3
$3.65M Buy
67,906
+9,174
+16% +$539K ﹤0.01% 1731
2022
Q2
$3.27M Buy
58,732
+20,359
+53% +$1.16M ﹤0.01% 1773
2022
Q1
$2.69M Sell
38,373
-29,171
-43% -$2.12M ﹤0.01% 2105
2021
Q4
$6.51M Buy
67,544
+10,267
+18% +$948K ﹤0.01% 1653
2021
Q3
$4.98M Buy
57,277
+893
+2% +$69.1K ﹤0.01% 1836
2021
Q2
$4.62M Buy
56,384
+10,064
+22% +$837K ﹤0.01% 1962
2021
Q1
$4.41M Buy
46,320
+37,536
+427% +$3.55M ﹤0.01% 1871
2020
Q4
$545K Buy
8,784
+5,168
+143% +$295K ﹤0.01% 4128
2020
Q3
$215K Sell
3,616
-23,548
-87% -$1.61M ﹤0.01% 4563
2020
Q2
$1.9M Sell
27,164
-13,656
-33% -$866K ﹤0.01% 2870
2020
Q1
$1.85M Buy
40,820
+15,962
+64% +$905K ﹤0.01% 2550
2019
Q4
$1.62M Sell
24,858
-832
-3% -$55.6K ﹤0.01% 3236
2019
Q3
$1.59M Buy
25,690
+2,490
+11% +$156K ﹤0.01% 3120
2019
Q2
$1.65M Sell
23,200
-9,041
-28% -$666K ﹤0.01% 3077
2019
Q1
$2.53M Sell
32,241
-66,768
-67% -$5.06M ﹤0.01% 2434
2018
Q4
$8.38M Buy
99,009
+57,022
+136% +$6.08M 0.01% 1390
2018
Q3
$7.19M Buy
41,987
+30,473
+265% +$4.59M 0.01% 1524
2018
Q2
$1.49M Sell
11,514
-31,531
-73% -$3.52M ﹤0.01% 2962
2018
Q1
$4.43M Sell
43,045
-15,219
-26% -$1.51M ﹤0.01% 1870
2017
Q4
$4.98M Buy
58,264
+8,311
+17% +$720K ﹤0.01% 1841
2017
Q3
$4.24M Sell
49,953
-1,784
-3% -$141K ﹤0.01% 1919
2017
Q2
$3.92M Buy
51,737
+4,035
+8% +$282K ﹤0.01% 1917
2017
Q1
$3.15M Sell
47,702
-88,090
-65% -$5.8M ﹤0.01% 2043
2016
Q4
$8.61M Buy
135,792
+111,157
+451% +$7.01M 0.01% 1311
2016
Q3
$1.57M Buy
24,635
+14,972
+155% +$1.1M ﹤0.01% 2750
2016
Q2
$719K Sell
9,663
-11,208
-54% -$832K ﹤0.01% 3273
2016
Q1
$1.39M Sell
20,871
-41,793
-67% -$2.54M ﹤0.01% 2939
2015
Q4
$4.24M Buy
62,664
+2,712
+5% +$167K ﹤0.01% 1844
2015
Q3
$3.2M Buy
59,952
+57,839
+2,737% +$3.51M ﹤0.01% 2051
2015
Q2
$133K Sell
2,113
-710
-25% -$38.7K ﹤0.01% 4780
2015
Q1
$136K Sell
2,823
-17,683
-86% -$678K ﹤0.01% 4807
2014
Q4
$681K Buy
20,506
+4,551
+29% +$148K ﹤0.01% 3554
2014
Q3
$468K Buy
15,955
+14,506
+1,001% +$482K ﹤0.01% 3586
2014
Q2
$56K Sell
1,449
-460
-24% -$18.7K ﹤0.01% 5090
2014
Q1
$80K Sell
1,909
-8,889
-82% -$371K ﹤0.01% 5182
2013
Q4
$355K Buy
10,798
+4,307
+66% +$140K ﹤0.01% 4128
2013
Q3
$175K Buy
6,491
+6,201
+2,138% +$174K ﹤0.01% 4268
2013
Q2
$7K Buy
+290
New +$5.22K ﹤0.01% 6229

Other funds holding LGND

Citigroup's LGND Position: Q2 2026 in Review

Citigroup increased its Ligand Pharmaceuticals (LGND) stake by 209% in Q2 2026, buying an estimated $10.6M and bringing the position to 66,639 shares worth $21.1M. The position accounts for 0.01% of the portfolio, ranked #1145.

Citigroup first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Citigroup held 66,639 shares of Ligand Pharmaceuticals worth $21.1M as of Q2 2026.
  • Citigroup bought 45,045 Ligand Pharmaceuticals shares in Q2 2026, an estimated $10.6M.
  • Ligand Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q2 2026, its #1145 holding.
  • Citigroup first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.